Eutectic Mixture of Local Anaesthetics (EMLA) is recommended for use off-label as a treatment for premature ejaculation (PE). Other topical anaesthetics are available, some of which have been evaluated against oral treatments. The purpose of this systematic review was to evaluate the evidence from randomised controlled trials (RCTs) for topical anaesthetics in the management of PE. Bibliographic databases including MEDLINE were searched to August 2014. The primary outcome was intra-vaginal ejaculatory latency time (IELT).
Introduction
Premature ejaculation (PE) is commonly defined by a short ejaculatory latency, a perceived lack of ejaculatory control; both related to self-efficacy; and distress and interpersonal difficulty.
1 PE can be either lifelong (primary), present since first sexual experiences, or acquired (secondary), beginning later. 2 A range of definitions for PE exist, having been drafted by various professional organisations. 3, 4 The recently updated
International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature
Ejaculation (PE) propose that PE is a male sexual dysfunction characterised by ejaculation within approximately 1 min of vaginal penetration (lifelong PE) or a reduction in latency time to  3 min (secondary PE), the inability to delay ejaculation, and negative personal consequences.
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The treatment of PE should attempt to alleviate concern about the condition as well as increase sexual satisfaction for the patient and the partner. 6 Available treatment pathways for the condition are varied and treatments may include both behavioural and/or pharmacological interventions. The use of local anaesthetics to delay ejaculation reduces the sensitivity of the glans penis thereby delaying ejaculatory latency, but without adversely affecting the sensation of ejaculation. 7 Based on randomised controlled trial (RCT) evidence, the European Association of Urology guidelines for the management of PE recommend on-demand topical lidocaine-prilocaine cream. 8 Systematic reviews that have presented a meta-analysis have either not been able to pool data across all RCTs due to missing data, 9 or have pooled outcome measures reported as arithmetic or geometric means together using a standardised mean difference.
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The aim of this study was to systematically review the evidence for topical anaesthetics in the management of PE, by summarising evidence from randomised controlled trials (RCTs) and to undertake a meta-analysis across the current evidence base.
Methods
The review was undertaken in accordance with the general principles recommended in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
Searches
The following databases were searched from inception to 5 August 2014 for published and unpublished Existing systematic reviews were also checked for eligible studies. All citations were imported into Reference
Manager Software (version 12, Thomson ResearchSoft, Carlsbad, California) and any duplicates deleted.
Eligible studies
Randomised control trials recruiting adult men with PE were included. RCTs that evaluated Severance Secret cream (SS-cream -a topical plant-based preparation comprising extracts of nine plants) were excluded as this agent is available for use only in one country (Korea). 13 RCTs that evaluated other topical anaesthetic agents were eligible for inclusion. Randomised cross-over design studies were excluded to avoid double counting of participants in the meta-analysis. Theses and dissertations were not included. Non-English publications were included where sufficient data could be extracted from an English-language abstract or tables.
Outcomes
The primary outcome was intra-vaginal ejaculatory latency time (IELT). Other outcomes included sexual satisfaction, control over ejaculation, relationship satisfaction, self-esteem, quality of life, treatment acceptability and adverse events.
Data extraction
One reviewer performed data extraction of each included study. All numerical data were then checked by a second reviewer.
Methodological quality of studies Methodological quality of RCTs was assessed using the Cochrane Collaboration risk of bias assessment criteria.
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We classified RCTs as being at overall 'low' risk of bias if they were rated as such for all three of the following key domains -(i) allocation concealment; (ii) blinding of outcome assessment; and (iii) completeness of outcome data (attrition <30%). We classified RCTs as being at overall 'high' risk of bias if they were rated as such for any of these domains.
Data synthesis
Where possible, between-group differences for direct comparisons (e.g. selective serotonin re-uptake inhibitors (SSRI) vs placebo) were pooled across trials in a pairwise meta-analysis using Cochrane RevMan software (version 5.2) (RevMan 2012). 15 Continuous outcomes reported as arithmetic and geometric means were analysed separately as the mean difference (MD). Where standard deviations or standard errors were not presented in the trial report, these were estimated from the range (where reported) using the method described by Hozo et al. 16 For pooled comparisons where there was little apparent clinical heterogeneity and the I 2 value (I 2 statistic 17 ) was 40% or less, a fixed-effect model was applied. Random-effects models were applied where the I 2 value was >40%. Between-group effect estimates were considered significant at P < 0.05. Where more than five RCT comparisons were available, publication bias was assessed by visual inspection of funnel plots.
Results

Search results
The searches identified 2331 citations (as part of a wider project assessing a variety of treatments for PE).
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Of these, 2319 citations were excluded as titles/abstracts. Twelve full-text articles were obtained as potentially relevant. The study selection process is fully detailed in the PRISMA flow diagram in Fig. 1 . A total of nine RCTs that evaluated a topical anaesthetic agent against a comparator (placebo or another agent) were identified.
Details of the included RCTs, the comparator(s), outcomes assessed and the risk of bias assessment are detailed in Table 1 .
Risk of bias assessment of RCTs
The majority of RCTs were considered to be at an overall unclear risk of bias mainly due to lack of reporting of information to inform the risk of bias assessment. Only one RCT reported that a random sequence generation method, 18 and only one reported that treatment allocation was concealed. 19 One RCT prescribed either an oral or a topical treatment to treatment groups and as such, participants and caregivers would not have been blinded.
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One RCT was described as being single-blind. 18 Both these RCTs were considered to be at high risk of performance bias. In one RCT, numbers withdrawing were imbalanced across groups [placebo 44%, Eutectic
Mixture of Local Anaesthetics (EMLA), 28%] and data were analysed per-protocol (withdrawals exclude).
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One reported that 30% of participants withdrew overall but did not reported how many withdrew by treatment group. 21 Both RCTs were considered to be at an overall high risk due to attrition bias. A summary of the risk of bias assessment for each included RCT is presented in Fig. 2 .
Characteristics of RCTs
Randomised control trial details of the treatments, efficacy and safety outcomes, and the risk of bias assessment are presented in Outcome data reported by RCTs
With the exception of the RCT by Atan et al., 20 IELT was assessed by all of the included RCTs (Table 1, Figs 3, 4) . Where reported, the assessment method was by stopwatch. The reporting of other efficacy outcomes was much more varied, both in the assessment method and the outcome data available (Table 1) . Across the majority of RCTs, outcome data for adverse event reporting was disparate in terms of limited reporting of types of adverse events and patient numbers.
Data synthesis
Intra-vaginal ejaculatory latency time as a mean outcome with a variance estimate was available for all but two RCTs that reported IELT outcomes, but without any variance estimates. Mallat et al. 26 reported a P-value for IELT of P < 0.001, but it was unclear if this was across or between groups, or whether this was for end of study values or change from baseline. Steggall et al. 21 reported a P-value for median IELT change from baseline of P = 0.038 for lidocaine spray and P < 0.0005 for paroxetine.
IELT: topical anaesthetics vs placebo
Meta-analysis of mean IELT (min) following an application of EMLA cream  20 min pre-intercourse, based on two RCTs (n = 49), displayed low heterogeneity (I 2 = 0%). The pooled mean difference (MD) in IELT was 6.44, significantly favouring EMLA [MD (fixed effect) 95% confidence interval (CI), 6.01 to 6.87; P < 0.00001]. The between-group difference in mean IELT (min) based on one RCT (n = 54), was 3.10, significantly favouring TEMPE spray [MD (fixed effect) 95% CI, 1.33 to 5.27; P = 0.001]. Meta-analysis of geometric mean IELT (min) based on two RCT study group comparisons (n = 49), displayed low heterogeneity (I 2 = 0%). The pooled MD in IELT was 2.10 significantly favouring TEMPE spray [MD (fixed effect) 95% CI, 1.27 to 2.93; P < 0.00001]. The between-group difference in end of study values based on one RCT (n = 57) was 3.29 min (95% CI 2.60 to 3.98; P < 0.00001), in favour of lidocaine gel. The forest plot for these analyses is presented in Fig. 3 .
Other outcomes: topical anaesthetics vs placebo Three RCTs did not report any effectiveness outcomes other than IELT (Atikeler et al. 2002; 25 Atan et al.
2006
; 20 Steggall et al. 2008 21 ) . A statistically significant between-group difference in sexual satisfaction in favour of EMLA cream after 2 months was reported by Busato and Galindo (2004) . 19 There appeared to be no difference between EMLA cream and placebo on the International Index of Erectile Dysfunction (IIEF) number of coitus per week and sexual satisfaction values reported by one RCT (Mallat et al. 2012) . 26 The betweengroup differences on the Index of Ejaculatory Control and Sexual Quality of Life (SQoL) for both men and women were reported as being not statistically significant at 4 weeks in one RCT comparing TEMPE with placebo (Dinsmore et al. 2007 23 ). However, two RCTs reported that the TEMPE spray was significantly more effective than placebo at 12 weeks on the Index of Premature Ejaculation (IPE) measures including ejaculatory control, sexual satisfaction and distress, and on the Premature Ejaculation Profile (PEP) 27 Carson and Wyllie 2010; 22 ). One RCT 18 reported that end of study mean improvement in sexual satisfaction was significantly higher with lidocaine gel than that of the placebo group (P < 0.05).
IELT: topical anaesthetics vs oral agent However, Atikeler et al. (2002) 25 reported that EMLA cream caused 6/10 men in the 30 min application group and 10/10 men in the 45 min application group to report erection loss or numbness.
The pooled relative risk (RR) across three trials comparing TEMPE spray with placebo (593 participants) was 3.25 [RR (fixed effect) 95% CI 1.50-7.02; P = 0.003] in favour of placebo (lower risk). The forest plot for this analysis is presented in Fig. 5 .
Adverse events were not reported for one RCT (Steggall et al. 2008 21 ). Where reported, adverse events associated with topical anaesthetics included: erectile dysfunction/loss of erection, loss of sensitivity/numbness (men and women) and irritation/burning (men and women). One RCT reported 22/30 (73%) participants receiving lidocaine gel reported penile anaesthesia in the lidocaine gel group, compared with none receiving sildenafil, paroxetine, tramadol or placebo. Greater sleep disturbance, dry mouth, nausea, dizziness, fatigue, vomiting, sweating and headache were reported with tramadol, sildenafil and paroxetine. All side-effects were reported as being tolerable.
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Discussion
The aim of this study was to systematically review the evidence for topical anaesthetics in the treatment of PE and to pool evidence from RCTs for the effects of topical anaesthetics on IELT in a mean difference metaanalysis. The present systematic review is an extension to our HTA (Health Technology Assessment) short report on treatments for premature ejaculation. 12 In the HTA short report, searches were run to August 2013 and rapid review methods were employed by extracting RCT outcome data reported in existing reviews without obtaining the RCT publication in full. Only RCTs not already captured by existing reviews were obtained in full for data extraction and assessment of methodological quality. The present review has run searches to August 2014, has applied full systematic review methods, obtaining in full all RTCs evaluating topical anaesthetics identified for inclusion for data extraction and assessment of methodological quality. 18, 20 were considered at high risk of performance bias as they were not of a double-blind. The majority of RCTs were considered at overall unclear risk of bias mainly due to lack of reporting of information to inform the risk of bias assessment. The findings should therefore be interpreted with caution given the methodological quality of the available evidence. Key aspects of best practice in RCT design to minimise bias include a robust randomisation method, concealment of treatment group allocation, and, where possible, blinding of participants and trial personnel, and blinded outcome assessment; all of which should be clearly stated in the RCT report. 28 In addition, patient acceptability of this treatment modality (topical application) for PE has not been evaluated in the current evidence base.
Although our database search strategy was comprehensive, the possibility of a publication bias cannot be discounted. Insufficient numbers of RCT comparisons were available for a formal assessment of publication bias using funnel plots to be undertaken. Nonetheless, although the majority of RCTs identified for inclusion were of unclear methodological quality, it could be considered unlikely that any additional, unpublished data for the effects of topical anaesthetics would contribute significantly to the overall findings of this review.
The results observed by this review for the effectiveness of topical anaesthetics in the treatment of PE are comparable with other reviews. 9,10 However, where meta-analyses have previously been undertaken, IELT data reported as arithmetic means have been pooled with geometric means using a standardised mean difference.
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This review has pooled data across RCTs, where appropriate, in a meta-analysis using a mean difference to summarise IELT outcomes, analysing separately RCTs reporting geometric means (log-transformed). Logtransformed and untransformed data are not recommended to be pooled together in a meta-analysis.
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Furthermore, this review has been able to include evidence for topical anaesthetics compared with oral agents prescribed off-label for the treatment of PE.
The RCTs evaluating topical anaesthetics identified for inclusion in this review evaluated treatments over 4-12 weeks. None reported a long-term follow up on efficacy and safety outcomes or treatment persistence.
Systemic adverse events were more prevalent with oral treatments, which may make topical anaesthetics more acceptable. Likewise, the rapid action of topical anaesthetics compared with planning to take oral medication in advance might also be more acceptable. Conversely, the inconvenience of washing and transfer of the agent to the partner might be limiting factors to acceptability. Participant preference was not an outcome assessed by any RCT. However, more important is a requirement for clearer evaluations of the relationship between treatmentrelated increases in IELT, ejaculatory control and sexual satisfaction associated with topical anaesthetics. One RCT suggests that tramadol is more effective than topical anaesthetics at increasing IELT in men with PE; however, the long-term use of tramadol for the treatment of PE, in terms of a safety profile including addiction potential, is unclear from the current evidence base.
The European Association of Urology 2014 Guidelines on male sexual dysfunction recommend that pharmacological treatment options include 'on demand' dapoxetine, daily use of a longer-acting SSRI (off-label use), daily use of clomipramine (off-label use), 'on demand' topical lidocaine-prilocaine cream (off-label use) and 'on demand' tramadol (off-label use).
8 Given that topical anaesthetics have been extensively evaluated against placebo for the treatment of PE in the current evidence base, with limited head-to-head comparisons between topical anaesthetics and other treatments (paroxetine, sildenafil and tramadol), further direct comparisons between topical anaesthetics and other SSRIs, including dapoxetine and other PDE5 inhibitors, should now be investigated. While the observed increases in IELT were statistically significant in favour of topical anaesthetics for most comparators, it is difficult to quantify how acceptable and meaningful these changes are for men with PE, without being able to evaluate the relationship between IELT, ejaculation control and sexual satisfaction from the current RCT evidence-base for topical anaesthetics. The trade-off between IELT and other effectiveness outcomes versus adverse effects should also be further evaluated as should treatment acceptability and persistence.
Conclusion
Topical anaesthetics appear more effective than placebo, paroxetine and sildenafil at increasing IELT in men with PE. However, these findings should be interpreted with caution given the limited methodological quality of the available evidence.
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